Treating lupus nephritis to achieve sustained remission for at least 3 years likely protects kidney function. In patients with active lupus nephritis, at least 3 years of sustained clinical ...

Order expected to affect specific medications covered under Medicare that are administered in a health care setting. (HealthDay News) — Today, President Donald Trump signed an executive order ...

Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women. (HealthDay News) — Glucagon-like peptide-1 receptor ...

Pain control was achieved by TUF in 70.0 percent of 240 patients; 18 patients underwent cystectomy for intractable pain. (HealthDay News) — For patients with interstitial cystitis (IC ...

Credit: Getty Images These systems can feel punitive rather than developmental, leading to employee disengagement and feedback resistance. Healthcare organizations should prioritize transparent ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

More favorable diagnostic yield seen with annual versus biennial screening. (HealthDay News) — Annual multicancer early detection (MCED) screening with a single blood test provides more overall ...

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

Persistent hyperglycemia linked to increased odds of worsening left ventricular hypertrophy over seven years. (HealthDay News) — Adolescent hyperglycemia and worsening insulin resistance (IR ...

SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with lower incidence of epilepsy among patients with type 2 diabetes.